Explore

Privo Technologies Announces 95.5% Complete Response Rate for Non-Surgical Oral Cancer Therapy PRV111 in Phase 2 Trial

Privo Technologies Announces 95.5% Complete Response Rate for Non-Surgical Oral Cancer Therapy PRV111 in Phase 2 Trial

Privo Technologies has announced positive results from its CLN-004 Phase 2 trial for PRV111, a nanoengineered, cisplatin-releasing patch designed to treat non-invasive oral cancer and high-grade dysplasia. The study, conducted at four major U.S. hospitals, involved 22 patients with biopsy-confirmed conditions. Twenty-one of these patients (95.5%) achieved a centrally confirmed pathologic complete response, meaning no residual dysplastic cells were found after treatment. The remaining patient was downstaged to low-grade dysplasia. Crucially, all 22 patients avoided the need for standard-of-care surgery, with treated lesions resolving and mucosal surfaces regenerating without scarring or distortion. At a median follow-up of 14 months, no recurrences were observed, and some patients have maintained responses for over 21 months. The treatment was well-tolerated, with negligible systemic cisplatin exposure and primarily mild, transient oral symptoms reported as treatment-related adverse events.

Illumina Seeks Oncology Medical Science Liaison to Advance Precision Medicine Research

Illumina Seeks Oncology Medical Science Liaison to Advance Precision Medicine Research

Illumina, a global leader in DNA and multi-omic sequencing, is actively seeking a Sr. Staff Medical Science Liaison (MSL) in Oncology. This role is crucial for advancing precision medicine research, particularly in the field of oncology. The selected individual will be responsible for demonstrating a comprehensive understanding of Illumina's product offerings, recent medical and scientific advancements, and key publications related to precision medicine in oncology. A core aspect of the position involves fostering and maintaining collaborative relationships with external scientific leaders and stakeholders. This engagement aims to facilitate scientific exchange, gather insights, and understand the evolving scientific, clinical, and research needs within the genomics community. The MSL will also manage relationships with healthcare professionals (HCPs), healthcare organizations (HCOs), professional societies, and customers across the U.S. to support scientific education and communication regarding genomic t...

Study Links High Polyphenol Intake, Especially from Coffee, to Lower Breast Cancer Mortality

Study Links High Polyphenol Intake, Especially from Coffee, to Lower Breast Cancer Mortality

A new observational study has found an association between higher polyphenol intake, particularly from coffee, and lower rates of breast cancer-related death among women diagnosed with the disease. The study followed 95 women with breast cancer for approximately 11 years, evaluating their consumption of polyphenols, which are naturally occurring plant compounds found in foods like coffee, fruits, vegetables, whole grains, and nuts. Women with the highest polyphenol intake showed an approximately 80% lower risk of dying from breast cancer compared to those with the lowest intake. Coffee emerged as the primary source of polyphenols in the participants' diets. Surgical oncologist Nadia Nocera Zachariah, M.D., with Baptist Health Cancer Care, emphasized that while the findings are encouraging, the study is observational and does not prove that polyphenols or coffee directly cause the reduction in mortality. She cautioned against over-interpretation, stating that coffee is not a substitute for standard medical ...

These infections are behind 1 in 8 cancer cases worldwide, study finds

These infections are behind 1 in 8 cancer cases worldwide, study finds

Roughly 2.2 million new cancer cases worldwide could be traced back to these two very common infections, a new study found.

U.S. Agencies Track Environmental Carcinogens and Exposures to Protect Public Health

U.S. Agencies Track Environmental Carcinogens and Exposures to Protect Public Health

Various U.S. agencies are actively involved in tracking environmental carcinogens and assessing human exposure to them. The Centers for Disease Control and Prevention (CDC) supports surveillance, biomonitoring, and environmental public health tracking. The National Institute for Occupational Safety and Health (NIOSH), part of the CDC, conducts occupational research related to environmental health. The National Institute of Environmental Health Sciences (NIEHS), an NIH institute, focuses on how environmental exposures influence human health and disease, including through its Superfund Research Program. The U.S. Environmental Protection Agency (EPA) assesses risks and enforces regulations concerning air, water, chemicals, and waste. These efforts collectively aim to understand the totality of a person’s environmental exposures across their life course, a concept known as the 'exposome,' which was proposed by cancer epidemiologist Christopher Wild in 2005. This comprehensive approach involves measuring chemic...

New Molecular Matching Approach Shows Promise for Longer Survival in Advanced Cancer Patients

New Molecular Matching Approach Shows Promise for Longer Survival in Advanced Cancer Patients

A study published in npj Genomic Medicine introduces a new computational approach, the Molecular Therapy Matching Score, designed to improve precision oncology by considering the entire molecular profile of a patient's tumor rather than focusing on single genomic alterations. This method integrates various genomic alterations and molecular information to assess how effectively a drug or combination therapy addresses the tumor's overall characteristics. A retrospective analysis of 540 patients with advanced or metastatic cancer, including common types like breast and colorectal cancer, revealed that higher Molecular Therapy Matching Scores were significantly associated with longer progression-free and overall survival. For instance, patients with 67–100% matching had a median progression-free survival of 9.0 months compared to 3.0 months for those with 0% matching. Similarly, median overall survival was 18.7 months versus 9.0 months, respectively. The study was primarily funded by CureMatch, the company beh...

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Manual Lymphatic Drainage (MLD) Utilized for Post-Surgical Recovery and Chronic Conditions

Manual Lymphatic Drainage (MLD) Utilized for Post-Surgical Recovery and Chronic Conditions

Manual Lymphatic Drainage (MLD) is a gentle massage technique gaining recognition for its role in managing various health conditions, including lymphedema, post-surgical swelling, and chronic fluid retention. Unlike traditional deep tissue massage, MLD employs light, rhythmic strokes specifically targeting the lymphatic system to facilitate the removal of waste products and excess fluid from the body's tissues. This technique is frequently recommended for individuals recovering from cosmetic, orthopedic, and general surgeries, as well as those undergoing breast, head, and neck cancer recovery. It also addresses issues like bruising, inflammation, scar tissue, and post-radiation swelling. Clients often report feeling relaxed, less swollen, and experiencing improved comfort and range of motion after sessions. The number of treatments required varies based on the specific condition, with post-surgical clients often benefiting from multiple sessions over several weeks, while chronic conditions may necessitate ...

Fenbendazole Not Approved for Human Cancer Treatment, Poses Risks

Fenbendazole Not Approved for Human Cancer Treatment, Poses Risks

Fenbendazole, an antiparasitic medicine used in veterinary medicine to treat certain worm infections in animals, is not approved for human use in the United States, particularly for cancer treatment. Despite online discussions and personal testimonials suggesting its efficacy against cancer, there is no reliable clinical evidence to support these claims. The drug works by interfering with microtubules in parasites, which are also present in cancer cells, leading to scientific interest. However, laboratory findings and animal studies do not translate directly to safe and effective human treatments. The U.S. Food and Drug Administration has not approved fenbendazole for any human use, and there is no established, clinically validated dosing regimen for human cancer. Individuals considering or currently using fenbendazole for cancer are strongly advised to consult their oncology team to discuss potential risks and available evidence-based treatments.

Woman with Weeks to Live Shares Breast Cancer Story to Urge Early Detection

Woman with Weeks to Live Shares Breast Cancer Story to Urge Early Detection

Whitney Brooks, a 34-year-old woman from Baton Rouge, Louisiana, is sharing her story of Stage 4 breast cancer with only weeks left to live, in an effort to encourage other women to prioritize early detection. Brooks was diagnosed with Stage 3 breast cancer at age 27, but she first noticed a lump in her breast when she was 25. She initially dismissed it as a boil and delayed seeking medical attention due to fear. The disease has since progressed, spreading throughout her body, leaving her unable to walk, use the restroom, or feed herself independently. Brooks was placed on hospice in July with a 90-day prognosis. Despite her critical condition, she is using her remaining time to advocate for women to be aware of changes in their bodies and to overcome fear in seeking timely medical care.

Physician Highlights Four Key Red Flags in Family Medical History for Health Risk Assessment

Physician Highlights Four Key Red Flags in Family Medical History for Health Risk Assessment

Dr. Akshay Syal, an internal medicine physician and NBC News medical contributor, has identified four significant red flags in a family medical history that individuals should be aware of and discuss with their doctors. These red flags include the occurrence of a disease at an unusually young age, multiple relatives on the same side of the family having the same disease, specific patterns in cancer diagnoses (such as multiple close relatives with breast, colorectal, or uterine cancer), and any known genetic conditions or gene mutations like Lynch syndrome. Dr. Syal emphasizes that while these indicators do not guarantee disease development, they provide crucial information for earlier risk identification and can influence screening or prevention strategies. He advises individuals to compile a detailed family tree, noting diseases, major health conditions, and age of diagnosis for biological relatives, and to share this information with their healthcare providers.

MercyOne Establishes Cardiac Response Network Across Iowa to Expedite Heart Attack Treatment

MercyOne Establishes Cardiac Response Network Across Iowa to Expedite Heart Attack Treatment

MercyOne has launched a Cardiac Response Network across Iowa to enhance and expedite care for patients experiencing severe heart attacks, specifically ST-elevation myocardial infarction (STEMI). This network integrates local hospitals, emergency medical services (EMS), and advanced cardiac care teams to ensure rapid access to life-saving treatment 24 hours a day, 7 days a week. The initiative focuses on standardized protocols, real-time communication, and seamless patient transfers. Key components include rapid ECG interpretation and communication, direct activation of cardiac catheterization teams, and coordinated ground and air medical transport. The program aims to reduce treatment delays and improve outcomes for heart attack patients by fostering collaboration among various healthcare providers, from rural hospitals and community emergency departments to specialized cardiovascular care facilities. The network ensures that regardless of where a cardiac emergency begins, patients receive timely diagnosis...